Tenax Therapeutics, Inc. (TENX)

Tenax Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	99.37	94.85	9.79	2.12	5.58	6.25
Short-Term Investments	-	-	-	-	-	0.46
Cash & Short-Term Investments	99.37	94.85	9.79	2.12	5.58	6.71
Cash Growth	1.08%	868.66%	361.09%	-61.97%	-16.82%	24.32%
Prepaid Expenses	3.44	1.77	1.64	0.74	0.11	0.08
Other Current Assets	-	0.06	0.25	0.35	-	-
Total Current Assets	102.81	96.69	11.68	3.21	5.69	6.8
Property, Plant & Equipment	-	-	-	0.19	0.29	0.06
Other Long-Term Assets	-	-	0	0.01	0.01	0.01
Total Assets	102.81	96.69	11.69	3.4	5.99	6.87
Accounts Payable	5.61	3.16	2.07	0.45	0.86	0.76
Accrued Expenses	0.99	1.54	1.01	0.66	0.6	1.18
Short-Term Debt	-	-	0.5	0.62	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.12
Current Portion of Leases	-	-	-	0.12	0.11	0.06
Total Current Liabilities	6.6	4.69	3.59	1.85	1.56	2.12
Long-Term Debt	-	-	-	-	-	0.12
Long-Term Leases	-	-	-	0.06	0.18	-
Total Liabilities	6.6	4.69	3.59	1.91	1.75	2.24
Common Stock	0	-	-	0	0	0
Additional Paid-In Capital	448.12	406.85	305.35	291.03	282.74	250.64
Retained Earnings	-351.91	-314.86	-297.25	-289.54	-278.49	-246.02
Comprehensive Income & Other	-	-	-	-	-	-0
Total Common Equity	96.21	91.99	8.1	1.49	4.24	4.63
Shareholders' Equity	96.21	91.99	8.1	1.49	4.24	4.63
Total Liabilities & Equity	102.81	96.69	11.69	3.4	5.99	6.87
Total Debt	-	-	0.5	0.81	0.29	0.31
Net Cash (Debt)	99.37	94.85	9.29	1.32	5.29	6.41
Net Cash Growth	1.08%	920.89%	606.12%	-75.14%	-17.40%	22.56%
Net Cash Per Share	2.61	6.21	37.40	71.55	411.57	-
Filing Date Shares Outstanding	40.57	35.85	1.96	0.35	0.02	-
Total Common Shares Outstanding	40.23	35.3	0.3	0.03	0.02	-
Working Capital	96.21	91.99	8.1	1.36	4.13	4.68
Book Value Per Share	2.39	2.61	27.15	52.11	269.43	-
Tangible Book Value	96.21	91.99	8.1	1.49	4.24	4.63
Tangible Book Value Per Share	2.39	2.61	27.15	52.11	269.43	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q